Health Care Providers' Experiences of a Mandatory Nationwide Transition to an Adalimumab Biosimilar.

ABSTRACT:

Objective

Transitioning patients to biosimilars has become common to reduce costs and improve access. However, it is unclear how the transition process impacts health care providers at the frontline of the brand change. This study explores health care providers' experiences of a mandatory brand change to an adalimumab biosimilar.

Methods

A cross-sectional study was conducted in Aotearoa New Zealand with 164 providers involved in the nationwide adalimumab brand change. Rheumatologists (n = 39), rheumatology nurses (n = 16), and pharmacists (n = 109) completed a survey that assessed their satisfaction with logistics and supply, information and education, support, and administrative workload and reported what did and did not go well during the transition.

Results

The mea

SUBMITTER: Gasteiger C 

PROVIDER: S-EPMC10716803 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature